Related Experiment Video
Updated: Sep 17, 2025
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Can multiplex molecular panels of microbial pathogens transform respiratory care in critically ill patients?
Julien Dessajan1, Valentine Berti2,3, Laurence Armand-Lefèvre2
1Medical and Infectious Diseases ICU (MI2), AP-HP, Bichat Hospital, Université Paris Cité, Paris, France.
Introduction:
Diagnosing severe pneumonia accurately is often difficult because its clinical symptoms overlap with other respiratory illnesses. Treatment of severe lower respiratory tract infection (LRTI) should start early. Rapid identification of responsible microorganisms and appropriate, not overly broad, antibiotic therapy is required to optimize prognosis. Unfortunately, the causative pathogen is often unidentified in pneumonia patients, and conventional bacterial cultures lack sensitivity and have slow turnaround times. Multiplex PCR (mPCR) respiratory panels, which quickly detect multiple bacterial pathogens, some common respiratory viruses, and key resistance genes, have become commercially available and may help achieve these objectives.
Areas Covered:
The authors will describe the available biological and clinical data on the benefits of mPCR in severe LRTI.
Expert Opinion:
mPCR offers early pathogen and resistance detection. However, mPCR panels do not detect all bacterial pathogens and may not differentiate between colonizing and infecting organisms. Detectable resistance genes do not always indicate phenotypic resistance. It should only be used in patients with adequate lower respiratory tract (LRT) samples. Additionally, evidence on whether mPCR panels improve antimicrobial use and patient outcomes remains limited and conflicting. This review provides a thorough overview of the rationale and clinical evidence for the use of mPCR panels for the detection of viral and bacterial pathogens in pneumonia diagnosis and management, as well as future research directions. [Figure: see text].
Insights
Multiplex PCR (mPCR) aids in early detection of pathogens and resistance in severe lower respiratory tract infections (LRTI). However, its clinical utility requires further evidence regarding antimicrobial use and patient outcomes.
Area of Science:
- * Infectious Disease
- * Clinical Microbiology
- * Respiratory Medicine
Background:
- * Accurate diagnosis of severe pneumonia is challenging due to overlapping symptoms with other respiratory illnesses.
- * Early treatment of severe lower respiratory tract infections (LRTI) is crucial for optimal prognosis.
- * Conventional bacterial cultures are often insensitive and slow for pathogen identification in pneumonia.
Purpose of the Study:
- * To review biological and clinical data on the benefits of multiplex PCR (mPCR) in severe LRTI.
- * To provide an overview of the rationale and clinical evidence for mPCR in pneumonia diagnosis and management.
- * To discuss future research directions for mPCR in respiratory infections.
Main Methods:
- * Review of available biological and clinical data on mPCR panels for respiratory pathogens.
- * Analysis of mPCR capabilities in detecting bacterial pathogens, common respiratory viruses, and resistance genes.
- * Evaluation of current evidence on the impact of mPCR on antimicrobial use and patient outcomes.
Main Results:
- * Multiplex PCR (mPCR) enables rapid detection of multiple pathogens and key resistance genes, potentially aiding early diagnosis.
- * Limitations include incomplete pathogen detection, inability to differentiate colonization from infection, and resistance genes not always indicating phenotypic resistance.
- * Evidence on mPCR's impact on improving antimicrobial use and patient outcomes in severe LRTI remains limited and conflicting.
Conclusions:
- * mPCR offers a rapid diagnostic tool for severe LRTI, but its clinical application requires careful consideration of sample quality and interpretation of results.
- * Further research is needed to clarify the benefits of mPCR in optimizing antimicrobial therapy and improving patient outcomes.
- * The role of mPCR in pneumonia diagnosis and management is evolving, with ongoing investigations into its full clinical utility.
Related Concept Videos
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
01:30Acute Respiratory Failure-III
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care